Is Dianthus Therapeutics, Inc. overvalued or undervalued?

As of 21 March 2024, Dianthus Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a Price to Book Value of 1.84, an EV to Sales ratio of 52.61, and a ROCE of -178.65%.
In comparison to its peers, Dianthus has a P/E ratio of -5.51, while Protagonist Therapeutics, Inc. is deemed expensive with a P/E of 60.90, and Deciphera Pharmaceuticals, Inc. also carries a risky valuation with a P/E of -11.62. The company's recent stock performance has lagged significantly behind the S&P 500, with a year-to-date return of -21.10% compared to the S&P 500's 2.44%, reinforcing the perception of overvaluation.